Small Cell Lung Cancer (SCLC) Clinical Trials

Find Small Cell Lung Cancer (SCLC) Clinical Trials Near You

Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants With Advanced Small Cell Lung Cancer

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Participants must be able to understand and sign the written informed consent form for participation in this trial, including all evaluations and procedures specified in this protocol.

• Male or female participants aged ≥18 years and ≤75 years.

• Participants with histologically or cytologically confirmed advanced small cell lung cancer.

• At least one measurable lesion according to RECIST V1.1 within 28 days prior to the first dose of IBI115.

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

• Expected survival period ≥12 weeks.

• Adequate bone marrow and organ function confirmed during the screening period.

Locations
Other Locations
China
the second affiliated hospital of AMU
RECRUITING
Chongqing
Contact Information
Primary
Xiao Zhang
kobe.zhang@innoventbio.com
+86 021 3183 7200
Time Frame
Start Date: 2026-05-21
Estimated Completion Date: 2030-03-30
Participants
Target number of participants: 150
Treatments
Experimental: IBI115
Subjects will receive IBI115 therapy until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of treatment with IBI115 is 24M.
Related Therapeutic Areas
Small Cell Lung Cancer (SCLC)
Lung Cancer
Sponsors
Leads: Innovent Biologics (Suzhou) Co. Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

Enrollment Status: Recruiting
Publish Date: March 18, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors

Enrollment Status: Recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Combination product
Study Phase: Phase 1
View All